Influence of baseline demographic characteristics on efficacy of a selective oral TYK2 inhibitor, BMS-986165, in patients with moderate-to-severe plaque psoriasis in a phase 2, randomized, placebo-controlled trial

doi:10.1016/j.jaad.2019.06.322

Influence of baseline demographic characteristics on efficacy of a selective oral TYK2 inhibitor, BMS-986165, in patients with moderate-to-severe plaque psoriasis in a phase 2, randomized, placebo-controlled trial

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2019.06.322 ◽

2019 ◽

Vol 81 (4) ◽

pp. AB82

Keyword(s):

Plaque Psoriasis ◽

Controlled Trial ◽

Demographic Characteristics ◽

Phase 2 ◽

Severe Plaque Psoriasis ◽

Baseline Demographic

Download Full-text

Influence of baseline demographics/disease characteristics on efficacy of an oral selective TYK2 inhibitor, BMS-986165, in patients with moderate to severe plaque psoriasis: Phase 2, randomized, placebo-controlled trial

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.3.supp.14 ◽

2019 ◽

Vol 3 ◽

pp. S14

Author(s):

K Gordon ◽

K Papp ◽

M Gooderman ◽

D Thaci ◽

P Foley ◽

...

Keyword(s):

Plaque Psoriasis ◽

Controlled Trial ◽

Phase 2 ◽

Severe Plaque Psoriasis ◽

Disease Characteristics

Abstract not available.

Download Full-text

Efficacy, safety, and quality of life in patients with moderate-to-severe plaque psoriasis treated with mirikizumab (LY3074828) in a phase 2 study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2018.05.528 ◽

2018 ◽

Vol 79 (3) ◽

pp. AB126 ◽

Cited By ~ 1

Keyword(s):

Quality Of Life ◽

Plaque Psoriasis ◽

Phase 2 ◽

Severe Plaque Psoriasis ◽

Phase 2 Study

Download Full-text

Efficacy and safety of total glucosides of paeony combined with acitretin in the treatment of moderate-to-severe plaque psoriasis: a double-blind, randomised, placebo-controlled trial

European Journal of Dermatology ◽

10.1684/ejd.2016.2946 ◽

2017 ◽

Vol 27 (2) ◽

pp. 150-154 ◽

Cited By ~ 5

Author(s):

Chen Yu ◽

Xueli Fan ◽

Zhenlu Li ◽

Xiaoming Liu ◽

Gang Wang

Keyword(s):

Plaque Psoriasis ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Severe Plaque Psoriasis ◽

Total Glucosides Of Paeony

Download Full-text

27468 Bimekizumab short-term and longer-term infection rates in patients with moderate to severe plaque psoriasis: Analysis of pooled data from eight phase 2/3 clinical trials

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.598 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB146

Author(s):

Kristian Reich ◽

Yukari Okubo ◽

Kenneth B. Gordon ◽

Andrew Blauvelt ◽

April Armstrong ◽

...

Keyword(s):

Clinical Trials ◽

Plaque Psoriasis ◽

Phase 2 ◽

Infection Rates ◽

Short Term ◽

Severe Plaque Psoriasis ◽

Pooled Data

Download Full-text

CLinical Experience Acquired with Raptiva�(CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from extended treatment in an international, Phase III, placebo-controlled trial

JDDG Journal der Deutschen Dermatologischen Gesellschaft ◽

10.1111/j.1610-0387.2006.06111.x ◽

2006 ◽

Vol 4 (11) ◽

pp. 947-956 ◽

Cited By ~ 21

Author(s):

Wolfram Sterry ◽

Georg Stingl ◽

Richard G.B. Langley ◽

Hugh Zacharie ◽

Morad Lahfa ◽

...

Keyword(s):

Clinical Experience ◽

Plaque Psoriasis ◽

Controlled Trial ◽

Phase Iii ◽

Severe Plaque Psoriasis ◽

Extended Treatment

Download Full-text

The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.14015 ◽

2016 ◽

Vol 31 (3) ◽

pp. 507-517 ◽

Cited By ~ 62

Author(s):

K. Reich ◽

M. Gooderham ◽

L. Green ◽

A. Bewley ◽

Z. Zhang ◽

...

Keyword(s):

Plaque Psoriasis ◽

Controlled Trial ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Phase Iiib

Download Full-text

Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the Susta IMM phase 2/3 trial

The Journal of Dermatology ◽

10.1111/1346-8138.14941 ◽

2019 ◽

Vol 46 (8) ◽

pp. 686-694 ◽

Cited By ~ 17

Author(s):

Mamitaro Ohtsuki ◽

Hideki Fujita ◽

Mitsunori Watanabe ◽

Keiko Suzaki ◽

Mary Flack ◽

...

Keyword(s):

Plaque Psoriasis ◽

Japanese Patients ◽

Phase 2 ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis

Download Full-text

IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis

Clinical Immunology ◽

10.1016/j.clim.2016.09.015 ◽

2017 ◽

Vol 174 ◽

pp. 63-72 ◽

Cited By ~ 37

Author(s):

Deepak M.W. Balak ◽

Martijn B.A. van Doorn ◽

Robert D. Arbeit ◽

Rianne Rijneveld ◽

Erica Klaassen ◽

...

Keyword(s):

Plaque Psoriasis ◽

Controlled Trial ◽

Clinical Activity ◽

Toll Like Receptor ◽

Severe Plaque Psoriasis

Download Full-text

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

British Journal of Dermatology ◽

10.1111/bjd.14164 ◽

2015 ◽

Vol 173 (6) ◽

pp. 1387-1399 ◽

Cited By ~ 201

Author(s):

C. Paul ◽

J. Cather ◽

M. Gooderham ◽

Y. Poulin ◽

U. Mrowietz ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Plaque Psoriasis ◽

Controlled Trial ◽

Phase Iii ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2019.08.019 ◽

2020 ◽

Vol 82 (2) ◽

pp. 389-397 ◽

Cited By ~ 7

Author(s):

Amy S. Paller ◽

Ying Hong ◽

Emily M. Becker ◽

Raul de Lucas ◽

Maria Paris ◽

...

Keyword(s):

Plaque Psoriasis ◽

Pediatric Patients ◽

Phase 2 ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Severe Plaque Psoriasis

Download Full-text